Skip to content

CHOlesterol effects of KOri-Tofu

CHOlesterol effects of KOri-Tofu - Choko

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51228
Enrollment
48
Registered
2021-04-08
Start date
2021-08-23
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood cholesterol levels

Interventions

Research subjects will receive 4 slices/buns of bread per day, representing a Kori-tofu dose of 34.5 gram or a matched reference (incl. whey protein, soy oil to and maltodextrin/cellulose), in rando

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Age between 40-70 years; * BMI between 18.5-35 kg/m2; * Total cholesterol levels >5 mmol/L or LDL >3 mmol/L

Exclusion criteria

Exclusion criteria: * Use of medication/supplements/food items that may influence the study results, such as cholesterol lowering medication, Becel ProActiv (judged by our research physician); * Total cholesterol levels >7 mmol/L; * LDL cholesterol levels >5 mmol/L; * Reported slimming, medically prescribed or other extreme diets; * Reported weight loss or weight gain of >5 kg in the month prior to pre-study screening; * Not willing to give up blood donation during the study; * Current smokers; * Alcohol intake *4 glasses of alcoholic beverages per day; * Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported); * Abuse of drugs; * Food allergies or intolerances for products that we use in the study; * Participation in another clinical trial at the same time; * Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

Design outcomes

Primary

MeasureTime frame
Main study parameters are fasting total and LDL cholesterol levels.

Secondary

MeasureTime frame
Secondary study outcomes are blood pressure and other markers of lipid metabolism, namely: HDL cholesterol, triglycerides levels, leptin and adiponectin. Secondary study outcomes also include markers of glucose metabolism: plasma insulin levels, HbA1c, fructosamine and glucose.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)